Aliases & Classifications for Bone Cancer

MalaCards integrated aliases for Bone Cancer:

Name: Bone Cancer 12 41 14
Bone Carcinoma 12 14 69
Malignant Bone Neoplasm 12 69
Bone Neoplasms 42 69
Malignant Neoplasm of Bone 12
Malignant Osseous Tumor 12
Malignant Bone Tumour 12
Osteosarcoma of Bone 69
Osteogenic Neoplasm 69
Ca - Bone Cancer 12
Neoplasm of Bone 12
Bone Neoplasm 12
Osseous Tumor 12
Bone Tumour 12

Classifications:



External Ids:

Disease Ontology 12 DOID:184 DOID:2762
MeSH 42 D001859
NCIt 47 C9343 C36082

Summaries for Bone Cancer

MedlinePlus : 41 cancer that starts in a bone is uncommon. cancer that has spread to the bone from another part of the body is more common. there are three types of bone cancer: osteosarcoma - occurs most often between ages 10 and 19. it is more common in the knee and upper arm. chondrosarcoma - starts in cartilage, usually after age 40 ewing's sarcoma - occurs most often in children and teens under 19. it is more common in boys than girls. the most common symptom of bone cancer is pain. other symptoms vary, depending on the location and size of the cancer. surgery is often the main treatment for bone cancer. other treatments may include amputation, chemotherapy, and radiation therapy. because bone cancer can come back after treatment, regular follow-up visits are important. nih: national cancer institute

MalaCards based summary : Bone Cancer, also known as bone carcinoma, is related to chest wall bone cancer and primary bone cancer, and has symptoms including back pain, muscle cramp and sciatica. An important gene associated with Bone Cancer is TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1). The drugs Quadramet and Xgeva have been mentioned in the context of this disorder. Affiliated tissues include bone, prostate and bone marrow.

Disease Ontology : 12 A connective tissue cancer that is located in bone and is characterized by uncontrolled cellular proliferation that destroys normal bone tissue.

Related Diseases for Bone Cancer

Diseases related to Bone Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 34)
id Related Disease Score Top Affiliating Genes
1 chest wall bone cancer 11.9
2 primary bone cancer 11.9
3 bone marrow cancer 10.9
4 ewing sarcoma 10.8
5 maxillary neoplasm 10.7
6 adamantinoma of long bones 10.7
7 osteosarcoma, somatic 10.7
8 bone squamous cell carcinoma 10.6
9 bone fracture 10.5
10 sternum cancer 10.5
11 femoral cancer 10.5
12 long bones of lower limb cancer 10.5
13 bone lymphoma 10.5
14 chondrosarcoma 10.5
15 jaw cancer 10.5
16 orbital cancer 10.5
17 multiple enchondromatosis, maffucci type 10.5
18 bone giant cell tumor 10.5
19 neuronitis 9.8
20 sarcoma 9.6
21 african histoplasmosis 9.5
22 skeletal tuberculosis 9.5
23 histoplasmosis 9.5
24 tuberculosis 9.5
25 prostatitis 9.5
26 multiple myeloma 9.5
27 enchondroma 9.5
28 muscular dystrophy 9.4
29 pheochromocytoma 9.4
30 prostate cancer 9.4
31 neuroma 9.4
32 colitis 9.3
33 fibrous dysplasia 9.3
34 osteoporosis 9.3

Graphical network of the top 20 diseases related to Bone Cancer:



Diseases related to Bone Cancer

Symptoms & Phenotypes for Bone Cancer

UMLS symptoms related to Bone Cancer:


back pain, muscle cramp, sciatica

Drugs & Therapeutics for Bone Cancer

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Quadramet 17 SAMARIUM SM-153 LEXIDRONAM PENTASODIUM DuPont Merck Pharmaceutical Company March 1997
2
Xgeva 17 46 DENOSUMAB Amgen June 2013/ November 2010
3
Xofigo 17 46 RADIUM RA-223 DICHLORIDE Bayer Healthcare Pharmaceuticals May 2013
4
Zometa 17 46 ZOLEDRONIC ACID Novartis August 2001/ February 2002

Drugs for Bone Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 917)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zoledronic acid Approved Phase 4,Phase 2,Phase 3,Phase 1 118072-93-8 68740
2
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 112809-51-5 3902
3
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-23-7 5754 657311
4
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
5
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
6
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 179324-69-7 387447 93860
7
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-02-2 5743
8
Doxorubicin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 23214-92-8 31703
9
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 120511-73-1 2187
10
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
11 Thiotepa Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 52-24-4 5453
12
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-22-0 6013
13
Bleomycin Approved Phase 4,Phase 3,Phase 1,Phase 2 11056-06-7 5360373
14
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
15
Teriparatide Approved, Investigational Phase 4,Phase 3 52232-67-4 16133850
16
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2 57-83-0 5994
17
Cisplatin Approved Phase 4,Phase 2,Phase 3,Phase 1 15663-27-1 84093 441203 2767
18 sodium fluoride Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7681-49-4
19
Menthol Approved Phase 4,Phase 3,Phase 1,Phase 2 2216-51-5 16666
20
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
21
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
22
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
23
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
24
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 55-98-1 2478
25
Dopamine Approved Phase 4,Phase 3,Phase 2,Early Phase 1 51-61-6, 62-31-7 681
26
Methamphetamine Approved, Illicit Phase 4 537-46-2 10836
27
Pamidronate Approved Phase 4,Phase 3,Phase 2,Phase 1 40391-99-9 4674
28
Etidronic acid Approved Phase 4,Phase 3,Phase 1 7414-83-7, 2809-21-4 3305
29
Protein C Approved Phase 4,Phase 2
30
Methoxyflurane Approved, Vet_approved Phase 4 76-38-0 4116
31
Adalimumab Approved Phase 4 331731-18-1 16219006
32
Nitrous oxide Approved, Vet_approved Phase 4,Phase 3 10024-97-2 948
33
Phentolamine Approved Phase 4 50-60-2 5775
34
Eszopiclone Approved Phase 4 138729-47-2 969472
35
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
36
Nevirapine Approved Phase 4 129618-40-2 4463
37
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
38
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 185243-69-0
39
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-28-2 5757
40
Ethinyl Estradiol Approved Phase 4,Phase 3 57-63-6 5991
41
Norethindrone Approved Phase 4,Phase 2 68-22-4 6230
42
Glycerol Approved, Investigational Phase 4,Phase 2 56-81-5 753
43
Aprepitant Approved, Investigational Phase 4,Phase 3 170729-80-3 151165 6918365
44
Fosaprepitant Approved Phase 4,Phase 3 172673-20-0 219090
45
Ondansetron Approved Phase 4,Phase 3,Phase 2 99614-02-5 4595
46
Denosumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 615258-40-7
47
Ephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2 299-42-3 9294
48
Pseudoephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2 90-82-4 7028
49
Radium Ra 223 dichloride Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 444811-40-9
50
Micafungin Approved, Investigational Phase 4,Phase 3,Phase 1 235114-32-6 3081921 477468

Interventional clinical trials:

(show top 50) (show all 3837)

id Name Status NCT ID Phase Drugs
1 Evaluate the Relationship of Bone Remodeling Markers for Skeletal Complications in Metastatic Breast Cancer Patients Unknown status NCT00912938 Phase 4 zoledronic acid
2 Assessment of Quality of Life, Bone Density and Safety in Postmenopausal Breast Cancer Patients With Letrozole Therapy Unknown status NCT00913016 Phase 4
3 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
4 Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer Unknown status NCT00030758 Phase 4
5 Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace) Unknown status NCT01908556 Phase 4 Letrozole
6 Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma Unknown status NCT01249690 Phase 4 Bortezomib,Pirarubicin,Dexamethasone;Thalidomide,Pirarubicin,Dexamethasone
7 Changes in Knee Articular Cartilage Volume in Women on Aromatase Inhibitors Unknown status NCT00111241 Phase 4 aromatase inhibitors (letrozole, anastrozole)
8 Vitamin D and Glucose Metabolism in Pediatrics Unknown status NCT01386736 Phase 4 Vitamin D drops;Placebo drops
9 HLA Sensitization Following Major Cortical Allograft Bone Procedures Completed NCT00160719 Phase 4
10 Physical Characteristics of Retrieved Massive Allografts Completed NCT00160758 Phase 4
11 Bioactive Glass Granules in Filling of Bone Defects Completed NCT01304121 Phase 4
12 Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases Completed NCT00434447 Phase 4 Zoledronic acid
13 A Study to Assess the Short Term Efficacy of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Pain Due to Breast Cancer Completed NCT02553707 Phase 4 Ibandronate
14 A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease Completed NCT02564107 Phase 4 Ibandronate
15 FREE Study - Fracture Reduction Evaluation Completed NCT00211211 Phase 4
16 Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients Completed NCT01129336 Phase 4 Zoledronic acid;Standard Therapy
17 Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis Completed NCT00241111 Phase 4 zoledronic acid
18 Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis Completed NCT00237159 Phase 4 Zoledronic acid
19 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4 zometa
20 Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates Completed NCT00765687 Phase 4 bisphosphates
21 Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer Completed NCT00334139 Phase 4 Zoledronic Acid
22 Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis Completed NCT00035997 Phase 4 Zometa
23 Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid Completed NCT00172029 Phase 4 Zoledronic acid
24 Pamidronate Administration in Breast Cancer Patients With Bone Metastases Completed NCT00128297 Phase 4 Pamidronate
25 Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer Completed NCT00391690 Phase 4 Zoledronic acid
26 Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis Completed NCT00172003 Phase 4 Zoledronic acid
27 Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases Completed NCT00219219 Phase 4 Zoledronic acid
28 Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy Completed NCT00485953 Phase 4 risedronate
29 Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer Completed NCT00219271 Phase 4 Zoledronic acid
30 Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy Completed NCT00237146 Phase 4 Zoledronic acid
31 The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy Completed NCT00063609 Phase 4 zoledronic acid
32 Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions Completed NCT00029224 Phase 4 zoledronic acid
33 Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer Completed NCT00859027 Phase 4 risedronate;placebo
34 Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer Completed NCT00082277 Phase 4 Anastrozole;Risedronate Sodium
35 Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases Completed NCT00434317 Phase 4 Zoledronic acid
36 Non-small Cell Lung Cancer Registry Completed NCT00099541 Phase 4 zoledronic acid
37 Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases Completed NCT00242554 Phase 4 Zoledronic acid
38 The ODYSSEY TRIAL Phase IV Trial Evaluating the Palliative Benefit of Pamidronate or Zoledronic Acid in Breast Cancer Completed NCT01907880 Phase 4 Pamidronate;Zoledronic acid;placebo
39 Correlation of MR Thermal Imaging to Actual Size of Ablation During Laser Ablation Therapy Completed NCT00688038 Phase 4
40 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
41 A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates Completed NCT00172016 Phase 4 Zoledronic acid
42 Efficacy and Tolerability of Zoledronic Acid With Radiotherapy in Pts With Advanced Osteolytic Bone Lesions Completed NCT00171964 Phase 4 Zoledronic acid in combination with therapy
43 Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer Completed NCT00199485 Phase 4 Angelica Sinensis
44 A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation Completed NCT00067730 Phase 4 Drotrecogin Alfa (activated)
45 Prevention of Osteoporosis in Breast Cancer Survivors Completed NCT00567606 Phase 4
46 Danish Osteoporosis Prevention Study Completed NCT00252408 Phase 4 Hormone replacement therapy
47 Safety and Efficacy of Methoxyflurane for Treatment of Incident Pain Completed NCT00524927 Phase 4 Methoxyflurane;Normal Saline
48 An Alternative to A Fixed Schedule In Management Of Prostate Cancer Completed NCT01056562 Phase 4
49 Humira in Rheumatoid Arthritis - Do Bone Erosions Heal? Completed NCT00696059 Phase 4 Adalimumab (Humira)
50 Study of the Efficacy of Kalinox® 170 Bar in Adult Oncology Completed NCT00646945 Phase 4 50% Oxygen/50% Nitrous oxide premix (Kalinox 170 bar);50% Oxygen/50% Nitrogen premix

Search NIH Clinical Center for Bone Cancer

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: bone neoplasms

Genetic Tests for Bone Cancer

Anatomical Context for Bone Cancer

MalaCards organs/tissues related to Bone Cancer:

39
Bone, Prostate, Bone Marrow, Breast, Myeloid, T Cells, Lung

Publications for Bone Cancer

Articles related to Bone Cancer:

(show top 50) (show all 159)
id Title Authors Year
1
Simultaneous inhibition of NMDA and mGlu1/5 receptors by levo-corydalmine in rat spinal cord attenuates bone cancer pain. ( 28500623 )
2017
2
HDAC inhibitor TSA ameliorates mechanical hypersensitivity and potentiates analgesic effect of morphine in a rat model of bone cancer pain by restoring I1-opioid receptor in spinal cord. ( 28559159 )
2017
3
Alleviating Mechanical Allodynia and Modulating Cellular Immunity Contribute to Electroacupuncture's Dual Effect on Bone Cancer Pain. ( 28870114 )
2017
4
Antinociceptive Effect of Intrathecal Injection of Genetically Engineered Human Bone Marrow Stem Cells Expressing the Human Proenkephalin Gene in a Rat Model of Bone Cancer Pain. ( 28286408 )
2017
5
Bone cancer: Is the osteosarcoma genome targetable? ( 28776583 )
2017
6
Plasma-induced selectivity in bone cancer cells death. ( 28571751 )
2017
7
Normalizing GDNF expression in the spinal cord alleviates cutaneous hyperalgesia but not ongoing pain in a rat model of bone cancer pain. ( 27716965 )
2017
8
Multi-target treatment of bone cancer pain using synergistic combinations of pharmacological compounds in experimental animals. ( 28850433 )
2017
9
Multicenter experiences in temporal bone cancer surgery based on 89 cases. ( 28225795 )
2017
10
Hyperthermia effect and antibacterial efficacy of Fe(3+) /Co(2+) co-substitutions in I^-Ca3 (PO4 )2 for bone cancer and defect therapy. ( 28661574 )
2017
11
Morin Suppresses Astrocyte Activation and Regulates Cytokine Release in Bone Cancer Pain Rat Models. ( 28618070 )
2017
12
Recombinant protein transduction domain-Cu/Zn superoxide dismutase alleviates bone cancer pain via peroxiredoxin 4 modulation and antioxidation. ( 28391978 )
2017
13
Spinal miRNA-124 regulates synaptopodin and nociception in an animal model of bone cancer pain. ( 28887457 )
2017
14
Etanercept attenuates thermal and mechanical hyperalgesia induced by bone cancer. ( 28565880 )
2017
15
The Molecular Genetic Expression as a Novel Biomarker in the Evaluation and Monitoring of Patients With Osteosarcoma-Subtype Bone Cancer Disease. ( 28425009 )
2017
16
Neuron-restrictive silencer factor-mediated downregulation of I1-opioid receptor contributes to the reduced morphine analgesia in bone cancer pain. ( 28415063 )
2017
17
Teniposide ameliorates bone cancer nociception in rats via the P2X7 receptor. ( 28825192 )
2017
18
Retraction Statement: CXCL12/CXCR4 chemokine signaling in spinal glia induces pain hypersensitivity through MAPKs-mediated neuroinflammation in bone cancer rats. ( 28417467 )
2017
19
Bufalin attenuates cancer-induced pain and bone destruction in a model of bone cancer. ( 28840279 )
2017
20
Combined application of diclofenac and celecoxib with an opioid yields superior efficacy in metastatic bone cancer pain: a randomized controlled trial. ( 28484877 )
2017
21
Effect of alkylaminophenols on growth inhibition and apoptosis of bone cancer cells. ( 28728976 )
2017
22
Midazolam and ropivacaine act synergistically to inhibit bone cancer pain with different mechanisms in rats. ( 27841001 )
2017
23
STAT1 as a downstream mediator of ERK signaling contributes to bone cancer pain by regulating MHC II expression in spinal microglia. ( 27742579 )
2017
24
Alleviating Bone Cancer-induced Mechanical Hypersensitivity by Inhibiting Neuronal Activity in the Anterior Cingulate Cortex. ( 27428822 )
2016
25
Targeting glia for bone cancer pain. ( 27428617 )
2016
26
Fabrication and characterization of PVA/ODA-MMT-poly(MA-alt-1-octadecene)-g-graphene oxide e-spun nanofiber electrolytes and their response to bone cancer cells. ( 26838849 )
2016
27
Analgesic effect and possible mechanism of SCH772984 intrathecal injection on rats with bone cancer pain. ( 27275127 )
2016
28
Minocycline attenuates bone cancer pain in rats by inhibiting NFI_B in spinal astrocytes. ( 27157092 )
2016
29
Rho/ROCK acts downstream of lysophosphatidic acid receptor 1 in modulating P2X3 receptor-mediated bone cancer pain in rats. ( 27094551 )
2016
30
MRI-guided focused ultrasound robotic system for the treatment of bone cancer. ( 27422861 )
2016
31
Negative regulation of REST on NR2B in spinal cord contributes to the development of bone cancer pain in mice. ( 27732941 )
2016
32
Radiotherapy Suppresses Bone Cancer Pain through Inhibiting Activation of cAMP Signaling in Rat Dorsal Root Ganglion and Spinal Cord. ( 26989332 )
2016
33
Dibenzoyl-methane Derivatives as a Potential and Exciting New Therapy for the Treatment of Childhood Bone Cancer. ( 27793931 )
2016
34
Analgesic effects of adenylyl cyclase inhibitor NB001 on bone cancer pain in a mouse model. ( 27612915 )
2016
35
Activation of spinal MrgC-Gi-NR2B-nNOS signaling pathway by Mas oncogene-related gene C receptor agonist bovine adrenal medulla 8-22 attenuates bone cancer pain in mice. ( 27158400 )
2016
36
CREB-regulated transcription coactivator 1 enhances CREB-dependent gene expression in spinal cord to maintain the bone cancer pain in mice. ( 27060162 )
2016
37
WNT5A and Its Receptors in the Bone-Cancer Dialogue. ( 27355180 )
2016
38
The analgesic effect of rolipram is associated with the inhibition of the activation of the spinal astrocytic JNK/CCL2 pathway in bone cancer pain. ( 28025994 )
2016
39
Positive feedback regulation between microRNA-132 and CREB in spinal cord contributes to bone cancer pain in mice. ( 26919478 )
2016
40
A Single Intrathecal or Intraperitoneal Injection of CB2 Receptor Agonist Attenuates Bone Cancer Pain and Induces a Time-Dependent Modification of GRK2. ( 26935064 )
2016
41
Dual Therapeutic Action of a Neutralizing Anti-FGF2 Aptamer in Bone Disease and Bone Cancer Pain. ( 27506449 )
2016
42
Suppression of the acute upregulation of phosphorylated-extracellular regulated kinase in ventral tegmental area by a I1-opioid receptor agonist is related to resistance to rewarding effects in a mouse model of bone cancer. ( 28034513 )
2016
43
Evaluation of Bone Cancer Pain Induced by Different Doses of Walker 256 Mammary Gland Carcinoma Cells. ( 27676678 )
2016
44
Silencing Transient Receptor Potential Vanilloid Receptor Subtype I-Containing Sensory Neurons to Treat Bone Cancer Pain. ( 27176213 )
2016
45
Effect of systemic injection of heterogenous and homogenous opioids on peripheral cellular immune response in rats with bone cancer pain: A comparative study. ( 27703511 )
2016
46
Mas-Related Gene (Mrg) C Activation Attenuates Bone Cancer Pain via Modulating Gi and NR2B. ( 27152740 )
2016
47
Effects of Electroacupuncture Treatment on Bone Cancer Pain Model with Morphine Tolerance. ( 27672401 )
2016
48
Targeted drug delivery of near IR fluorescent doxorubicin-conjugated poly(ethylene glycol) bisphosphonate nanoparticles for diagnosis and therapy of primary and metastatic bone cancer in a mouse model. ( 27919267 )
2016
49
Mechanisms of PDGF siRNA-mediated inhibition of bone cancer pain in the spinal cord. ( 27282805 )
2016
50
Effect of music therapy on pain behaviors in rats with bone cancer pain. ( 27273935 )
2016

Variations for Bone Cancer

Copy number variations for Bone Cancer from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 70082 12 58138784 58142025 Amplification SAS Bone cancer
2 70083 12 58141509 58146230 Amplification CDK4 Bone cancer
3 71134 12 67700000 68661632 Amplification MDM2 Bone cancer

Expression for Bone Cancer

Search GEO for disease gene expression data for Bone Cancer.

Pathways for Bone Cancer

GO Terms for Bone Cancer

Sources for Bone Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....